Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

All Solid Tumors Clinical Trials

A listing of All Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (44) clinical trials

Submission of Stem Cell Transplant Data to CIBMTR and NMDP

Background: - In 2005, the United States Congress legislated that outcome data would be collected on all patients who have been recipients of a stem cell therapeutics product (including bone marrow, cord blood, or other such product) from a donor. The Health Services and Resources Administration (HRSA) awarded the contract ...

Phase N/A

Collecting and Storing Information From Patients With Cancer or Other Chronic Disease Who Have Undergone Neurobehavioral Assessments on Another Clinical Trial

OBJECTIVES: Primary - Determine the neurobehavioral function of patients with chronic illness by analyzing stored data collected from IRB-approved protocols comprising retrospective data collected on protocols that are now closed and prospective data from current and future protocols. Secondary - Determine the relationship between neurobehavioral functioning and medical, neuroimaging, neurologic, ...

Phase N/A

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

OBJECTIVES: Primary - Determine the maximum-tolerated dose (MTD) and recommended phase II dose of sorafenib in pediatric patients with relapsed or refractory solid tumors. - Determine whether pediatric patients with relapsed or refractory leukemia can tolerate the MTD of sorafenib for solid tumors. - Determine the tolerability, active N-oxide metabolite, ...

Phase

Study of Patients With Cancer or Precancerous Conditions

OBJECTIVES: - To follow and evaluate patients, longitudinally with cancer or precancerous conditions referred to the NIH Clinical Center Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific importance. - To allow, when clinically indicated, patients to receive standard care ...

Phase N/A

Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

OBJECTIVES: Primary - To compare pain rating in cancer patients undergoing bone marrow aspiration and biopsy (BMAB) treated with magnetic acupressure at bilateral large intestine 4 (LI 4) points vs sham acupressure at bilateral proximal fourth interosseus space of the hand. Secondary - To compare the duration of BMAB, patient's ...

Phase N/A

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

This is a phase 1, open-label, multicenter, dose escalation study that will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. The primary goal of the study is to identify the maximum tolerated dose (MTD), or optimal biological dose (OBD) that does not exceed the ...

Phase

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Phase

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

This is an open-label, Phase 1b, 3 Part (Part 1a, Part 1b, and Part 2), multi-center study. Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) ...

Phase

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

Phase

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

The study has four parts: part 1: Multi-arm Bayesian adaptive signal finding design in solid tumors and diffuse large B cell lymphoma (DLBCL); part 2: NIR178 schedule exploration in NSCLC; part 3: Further evaluation of intermittent dosing schedules of NIR178 in combination with PDR001 in additional tumor types, if part ...

Phase